Prelude Capital Management’s Acceleron Pharma XLRN Stock Holding History

Prelude Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,700	Closed	-$293K	–	2423
2021 Q3	$293K	Buy	+1,700	New	+$222K	0.01%	1142
2015 Q2	–	Sell	-500	Closed	-$19K	–	2159
2015 Q1	$19K	Buy	+500	New	+$19.9K	﹤0.01%	1759
2014 Q3	–	Sell	-500	Closed	-$17K	–	2232
2014 Q2	$17K	Buy	+500	New	+$16.7K	﹤0.01%	1753

Prelude Capital Management's XLRN Position: Q4 2021 in Review

Prelude Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 3,691 shares — an estimated $635K sold.

Prelude Capital Management first reported a position in XLRN in Q2 2014 and held it in 9 quarters. The position peaked at $1.27M in Q3 2018. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Prelude Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Prelude Capital Management sold 3,691 Acceleron Pharma shares in Q4 2021, an estimated $635K.
Prelude Capital Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 9 quarters.
Prelude Capital Management's Acceleron Pharma position peaked at $1.27M in Q3 2018.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.